Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

Moderna’s mRNA flu shot outperforms existing vaccines in Phase 3 trial, showing over 26% greater efficacy—paving the way for ...

The trial enrolled more than 40,800 adults 50 and older from 11 countries.

Moderna’s latest flu vaccine, based on similar mRNA technology integrated in its COVID-19 shot, displayed optimistic outcomes ...

Moderna has reported positive phase 3 results for its seasonal flu vaccine, mRNA-1010, which outperformed a standard-dose ...

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

The Trump administration may cut off federal funding to hospitals that provide gender-related treatments to children and ...

Moderna today reported promising relative vaccine efficacy (rVE) findings from a phase 3 trial of its seasonal mRNA flu ...

Moderna’s experimental mRNA-based flu vaccine demonstrated a stronger immune response than a currently available standard flu shot in a late-stage phase 3 trial, clearing a path for regulatory ...

Presented by Vaccinate Your Family{beacon} Health Care Health Care   The Big Story Senate set to vote on amendment rolling ...

Amid promising signs, officials urged caution, noting that the outbreaks vary by clade, response measures, and social ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.